Last reviewed · How we verify
Compound Azintamide Enteric-coated Tablets
Compound Azintamide Enteric-coated Tablets is a Small molecule drug developed by Xinhua Hospital, Shanghai Jiao Tong University School of Medicine. It is currently FDA-approved.
Compound Azintamide Enteric-coated Tablets are being studied in a clinical trial for the treatment of dyspeptic symptoms after cholecystectomy. The trial, NCT04786795, is comparing Compound Azintamide Enteric-coated Tablets to other interventions, including Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets.
At a glance
| Generic name | Compound Azintamide Enteric-coated Tablets |
|---|---|
| Sponsor | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Compound Azintamide Enteric-coated Tablets CI brief — competitive landscape report
- Compound Azintamide Enteric-coated Tablets updates RSS · CI watch RSS
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine portfolio CI
Frequently asked questions about Compound Azintamide Enteric-coated Tablets
What is Compound Azintamide Enteric-coated Tablets?
Who makes Compound Azintamide Enteric-coated Tablets?
What development phase is Compound Azintamide Enteric-coated Tablets in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing